Pharma Equity Group A/S

Pharma Equity Group A/S is a clinical-stage biopharmaceutical investment company listed on Nasdaq Copenhagen, headquartered in Hørsholm, Denmark, and founded in 2003. It primarily supports its key subsidiary, Reponex Pharmaceuticals A/S, in developing innovative local treatments for serious, acute, and chronic inflammatory diseases where existing therapies are suboptimal or absent, including bacterial peritonitis, chronic skin ulcers, Crohn’s disease, pouchitis, colorectal cancer, and colon adenomas. The company employs a drug repositioning strategy, advancing known drugs to clinical phase II or III through efficient, cost-effective processes, leveraging expertise in life sciences, investment, and business development to create patentable formulations with precision-targeted delivery that minimizes systemic side effects and reduces dosing needs. Pharma Equity Group A/S emphasizes strategic partnerships with industry networks and advisors to drive Reponex’s pipeline, which includes candidates like RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051, ultimately aiming to hand over projects for commercialization while fostering global healthcare improvements. This focused approach positions it as a dedicated player in early-stage biotechnology addressing unmet medical needs.